补肾壮骨法对非小细胞肺癌溶骨性骨转移放疗患者骨相关事件及再次出现骨转移干预的临床研究

Clinical study of using invigorating the kidney and strengthening the bones therapy to reduce the probability of SREs for NSCLC patients with bone metastasis who received radiotherapy

摘要:

目的：研究中药补肾壮骨法对非小细胞肺癌（non-small cell lung cancer，NSCLC）溶骨性骨转移患者放疗后疼痛控制、骨相关性事件（skeletal related events，SREs）及再次出现新的骨转移灶时间的干预作用。方法：选取符合标准的59例肺癌骨转移患者，用随机数字表法分为治疗组（n=30）及对照组（n=29）。对照组行骨转移灶放射治疗及双磷酸盐治疗，治疗组在放疗期间服用补肾壮骨类中药。结果：２组患者治疗前后疼痛的变化差异均有统计学意义（治疗组P=0.002，对照组P=0.001）。治疗组SREs的发生率低于对照组（P=0.036）。治疗组患者出现新的骨转移灶的时间间隔长于对照组[（24.81±1.99）周 vs. （19.57±1.61）周，P=0.026]。结论：中药补肾壮骨法不能控制放疗及双磷酸盐治疗的止痛效果，但能够降低SREs的发生率，并延长出现新骨转移灶的时间。

Abstract:

Objective：To investigate the intervention role of invigorating the kidney and strengthening the bones therapy in controlling the pain after radiotherapy，reducing incidences of skeletal related events（SREs） and delaying time of recurrent bone metastasis for non-small cell lung cancer（NSCLC） patients with bone metastasis who received radiotherapy. Methods：Totally 59 NSCLC patients with bone metastasis were divided into two groups by randomization：treatment group（n=30） and control group（n=29）. Patients in treatment group were treated by radiotherapy and biphosphonates and received concurrent invigorating the kidney and strengthening the bones therapy（a traditional Chinese medicine therapy）；patients in control group were only treated by radiotherapy and biphos－phonates. Results：There were significant differences in the pain changes between two groups（treatment group P=0.002，control group P=0.001）. Incidences of SREs were lower in treatment group than in control group（P=0.036）. Time interval of recurrent bone metas－tasis was longer in treatment group than in control group，（24.81±1.99） weeks vs. （19.57±1.61） weeks，P=0.026. Conclusions：Invigorating the kidney and strengthening the bones therapy cannot reduce the pain of radiotherapy and biphosphonates，but can reduce the incidences of SREs and delay the time of recurrent bone metastasis.